PubMed · 2010 · 85 citations · 0 references
Public HealthPharmacologyAntimicrobial PharmacotherapyAntimicrobial Resistance EpidemiologyTuberculosis ControlAntibiotic ResistanceMultidrug ResistanceMycobacterial DiagnosticsTuberculosis DiagnosisTuberculosis Diagnostic TestingTuberculosis EpidemiologyDrug Resistance TestingDrug Susceptibility AssaysGenotypic IdentificationMolecular Drug Susceptibility TestingMycobacterium Tuberculosis InfectionPhenotypic Drug Susceptibility TestingRifampicin Resistance TestingTuberculosis Drug Resistance
SETTING: National Tuberculosis Reference Laboratory, Addis Ababa, Ethiopia. OBJECTIVES: To determine the drug susceptibility pattern of Mycobacterium tuberculosis isolates and to genetically characterise multidrug-resistant tuberculosis (MDR-TB) isolates. DESIGN: A total of 107 M. tuberculosis isolates recovered during the period December 2005-August 2006 were tested for drug susceptibility against streptomycin, isoniazid, rifampicin and ethambutol (SHRE) using the proportion method on Löwenstein-Jensen medium. The MDR-TB isolates were tested against kanamycin, ciprofloxacin, capreomycin, D-cycloserine and ethionamide. Genotyping was performed using spoligotyping. RESULTS: MDR-TB was observed in one of the 44 new cases (2.3%) and 45/63 previously treated patients (71.4%). Drug susceptibility testing against second-line drugs (SLDs) showed that 26.1% of all MDR-TB isolates were susceptible to all SLDs tested and 73.9% were resistant to one or more classes of SLD. Extensively drug-resistant (XDR) TB was detected in two isolates (4.4%). T3_ETH was the predominant spoligotype, followed by CAS_KILI. In this African setting, no Beijing spoligotype was identified. CONCLUSION: Both MDR- and XDR-TB are present in Ethiopian patients. MDR-TB was found to be associated with T3 and Central Asian genotypes.